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ABSTRACT 
    More studies showed that diagnosis of cancer lead to occurrence of emotional 
problems in patient and his family. Fluoxetine is an anti-depression drug that used 
for treatment of Depression, Obsessive compulsive disorder, Panic disorder and 
nervous incontinence. The aim of this study was investigate the effect of fluoxetine 
on quality of life in patients with solid cancers. This is a randomized controlled 
clinical trial that has been done on two groups of patients each with 70 patients. 
One group received fluoxetine for 12 weeks and another group received placebo. In 
baseline and end of study, SF36 questionnaire were completed for all patients and 
results analyzed by statistical methods in SPSS.16. The most prevalent malignancy 
in case and control groups was gastric cancer with 40% and 42.9%, respectively. 
There wasn’t significant difference in QOL of patients in baseline between two 
groups but in the end of study, emotional-psychological health and vitality scores in 
case group was better than control group. In terms of physical symptoms and 
depression, the case group was better than control group. In start and end of study, 
in QOL score only difference was seen in physical activity which was better in case 
group than control group. Results showed that fluoxetine prescription in patients 
could recovery some dimensions of QOL and general health but not effect on some 
dimensions which probably related to short duration of fluoxetine prescription in 
patients. 
 
Conflicts of Interest: Declared None 
Funding: Ardabil University of Medical Sciences 
 
  
Keywords 
Solid cancer,  
Fluoxetine,  
QOL,  
General health 
 
Corresponding to: 
Anahita Zakeri, 
Faculty of Medicine, Ardabil 
University of Medical Science, 
Ardabil, Iran 
 
Email: 
anahita.zakeri2017@gmail.com 
 
Received: 7 Mar 2017    
Revised: 11 Apr 2017,  
Accepted: 20 Jun 2017 
 
 
 
 
     INTRODUCTION 
Despite the remarkable advances in medical science, 
cancer is one of the most important diseases of the present 
century and is the second leading cause of death after 
cardiovascular disease. At present, more than 7 million 
people in the world are losing their lives due to cancer, and 
more than 25 million people live with cancer [1]. Although 
today, diagnosis of cancer is not equivalent to imminent 
death but many studies in Western countries and some Asian 
countries have shown that such a diagnosis causes deep 
emotional and emotional problems in the patient and his 
family [2,3]. 
Psychological status and quality of life are emphasized as 
one of the effective aspects in the care of cancer patients. 
The World Health Organization defines the quality of life as 
a person's perception of his or her own lifestyle based on the 
culture and systems of value in which he lives and how it 
relates to the goals, expectations, standards and priorities of 
the individual [4]. 
Cancer, in comparison with other diseases, causes worry 
and anxiety and more complex psychological problems. 
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Almost, 85% of cancer patients experienced one mental 
diseases that most of them related to anxiety and depression 
disorders. The physiological and psychological effects of 
cancer on patients and their families cause profound changes 
in their lives [3,5-7]. 
Fluoxetine as an antidepressant drug from the group of 
serotonin reuptake inhibitors is used to treat depression, 
obsessive-compulsive disorder, panic disorder, and 
neurological abnormalities [8-9]. 
Higher prevalence of cancer and its side-effects have 
more effect on the qol in cancer patients. Since physical 
conditions affect the social and psychological functioning of 
a person, the term "quality of life" is focused on physical, 
psychological, economic and social factors [4]. 
Depression is occurred in 15% of general population and 
in cancer patients 2-3 time is more. Due to the complexity 
and limitations of caring for cancer patients, the reluctance 
of the patient and his family to diagnose discomfort and the 
presence of many other symptoms, the diagnosis of 
depression is often difficult in these patients [10]. Given the 
low cost of this drug, its availability and its benefits in 
treating depression and other anxiety disorders, the purpose 
of this study was to evaluate the effect of fluoxetine on the 
quality of life of patients with solid tumors. 
 
MATERIALS AND METHODS  
This is a randomized double blind clinical trial that has 
been done on 140 patients with solid cancer which referred 
to Aras clinic of Ardabil city hospital in 2013-2014.  
 
Inclusion criteria 
Patients with age>15, confirmed cancer, passed at least a 
year from the diagnosis of the disease and unknown 
psychological problems or being treated with psychosocial 
drugs were entered in the study. 
 In this study the sampling method is census and we 
select all patients with solid tumor under chemotherapy with 
stable status and non-acute during 2013-2014 and then 
divided in two case and control groups each with 70 patients. 
Case group received 20 mg fluoxetine and control group 
received placebo for 12 weeks. The QOL-SF36 
questionnaire will completed in the start and end of study 
and the CHQ completed for all patients in the end of study. 
SF-36 questionnaire included 36 items in 8 dimensions 
(Physical functioning, Role limitations due to physical 
health, Role limitations due to emotional problems, 
Energy/fatigue, Emotional wellbeing, Social functioning, 
Pain and general health) which each item has score between 
0 to 100. 
 This study registered in IRCT by code: 
IRCT2015012220751N1 and ethically approved by Ardabil 
University of Medical Science. In the event of drug side 
effects, patients withdraw from the study and drug is cut. 
Collected data analyzed by statistical methods such as Chi-
square for determine the relation between QOL levels 
between two case and control groups and used T-test for 
compare the mean score of QOL between two groups in 
whiten QOL dimensions in SPSS version 16. 
 
 RESULTS  
The mean age of patients in case and control groups were 
57.6±12 and 55.8±13 that the difference not significant. Of 
Table 1. Demographic data of patients 
Variables 
Case Control 
n % n % 
Illiterate 31 44.3 28 40 
Smoking user 13 18 9 13.4 
History of alcohol consumption 4 5 5 6.4 
Age mean 55.8±13 57.6±12 
 
Table 2. Compare mean of QOL in patient’s two groups in the beginning of study 
Items Group Mean SD p-value 
General mental health 
Case 59.4 18.1 
0.12 
Control 53.2 15.3 
General health 
Case 65.1 16.4 
0.2 
Control 62.1 18.3 
Physical functioning 
Case 65.5 19.8 
0.7 
Control 66.1 21.4 
Bodily pain 
Case 66.9 16.5 
0.8 
Control 67.8 14.1 
Role limitations because of physical health problems 
Case 59.2 12.7 
0.2 
Control 55.3 16.9 
Social functioning 
Case 61.4 17.6 
0.8 
Control 60.1 19.9 
Role limitations because of emotional problems 
Case 67.3 21.9 
0.5 
Control 66.4 20.9 
Vitality (energy/fatigue) 
Case 74.1 21.4 
0.08 
Control 66.9 23.6 
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all patients in two groups, 84.3% were illiterate, 31.4% were 
smoking user and 11.4% have the history of alcohol 
consumption (Table 1). 
The prevalent malignancy in case group with 40% and 
18% and in control group with 42.9% and 15% were gastric 
and colon cancer, respectively. The QOL in the beginning of 
study has not significant difference between two groups but 
in the end of study, general mental health and vitality in case 
group was significantly more than control group (Table 2).  
By assessment the QOL in two groups separately we 
showed that physical functioning in case group in the end of 
study had a significant improvement compared to the 
beginning of the study but in other parameters the difference 
not significant and in control group no improvement were 
seen in any dimension. The highest frequency was related to 
physical functioning and general mental health of patients in 
the case group, which was in good range (Table 3). 
In terms of general health problems and depression, the 
case group had a better situation than the control group but 
there was no significant difference between the two groups 
in terms of symptoms of anxiety and sleep disorders, social 
function and general health score (Table 4). 
 
DISCUSSION  
Some studies indicated that the severity of depression in 
fluoxetine-treated patients decreases and the quality of life 
increases. In this study, the QOL of patients in two group in 
the end of study after fluoxetine prescription observed that 
general mental health and vitality in case significantly was 
more than control group. Also physical functioning in case 
group patients in the end of study compared to the beginning 
of the study have significant recovery. In Fisch and et al 
study, results showed that the depression severity in treated 
patients with fluoxetine had been increased and QOL had 
been decreased [10]. 
  In Holland and et al study, results the fluoxetine and 
Desipramine prescription reduced the symptoms of 
depression and anxiety in patients and the FLIC (Functional 
Living Index for Cancer) function was also improved [8]. In 
QOL study these two drugs could improvement the 
dimensions of general mental health and social functioning 
in patients which in line with our study results, because in 
this study fluoxetine could improve the general mental 
health in patients but had not significant effect on social 
functioning and anxiety of patients.  
Passik and et al, in a study showed that the 
administration of fluoxetine for 12 weeks could improve the 
QOL of patients significantly [11]. In Navari and et al study, 
the depression symptoms in 79.6% of breast cancer patients 
which treated with fluoxetine has been decreased and QOL 
of patients has been increased [8,12]. 
Contrary to the current study, Razavi et al. found that 
Table 3. Study QOL level of patients in two groups in the end of study 
Items 
QOL levels 
Group 
Week Moderate Good p-value 
General mental health 
Case 7.1 21.4 71.4 
0.001 
Control 21.4 41.4 37.2 
General health 
Case 5.7 27.1 67.1 
0.24 
Control 8.6 35.7 55.7 
Physical functioning 
Case 2.9 22.9 74.2 
0.42 
Control 7.2 21.4 71.4 
Bodily pain 
Case 10 25.7 64.3 
0.64 
Control 14.3 27.1 58.6 
Role limitations because of physical health problems 
Case 17.1 37.1 45.7 
0.8 
Control 14.3 35.7 50 
Social functioning 
Case 10 31.4 58.6 
0.37 
Control 7.1 40 52.9 
Role limitations because of emotional problems 
Case 10 12.9 77.1 
0.7 
Control 10 17.1 72.9 
Vitality (energy/fatigue) 
Case 7.1 10 82.9 
0.26 
Control 4.3 17.1 78.6 
 
Table 4. Study General Health of patients in two groups in the end of study 
Items 
QOL levels 
Group 
Moderate Week Good p-value 
Anxiety symptoms and sleep disorders 
Case 33 44.3 23 
0.8 
Control 38.5 37.2 24.3 
Social functioning 
Case 24.3 58.6 17.1 
0.8 
Control 27.1 58.6 14.3 
Depression symptoms 
Case 27.1 68.6 4.3 
0.008 
Control 37.1 41.3 21.6 
General health problems 
Case 27.1 68.6 4.3 
0.028 
Control 40 51.4 8.6 
Total general health score 
Case 35/7 51.4 12.9 
0.15 
Control 35.7 41.4 22.9 
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fluoxetine did not significantly reduce depression in patients 
within 5 weeks. It seems that short-term administration of 
fluoxetine in this study was a contradiction in the results 
[13]. 
In a full review of the articles, fluoxetine was found to be 
effective in depression rate and quality of life in cancer 
patients, which in current study the significant relation, was 
seen in many dimension of QOL in patients [14]. 
In Torta and et al study, it was observed that prescription 
of sertralin for 12 weeks could reduce significantly MADRS 
(Montgomery Asberg Depression Rating Scale) and HADS 
(Hospital Anxiety and Depression Scale) and in 40.4% of 
patients the rate of depression has improved greatly [15]. 
In Grassi and et al, it was observed that Administration 
of 8-week reboxetine significantly reduced the level of 
anxiety and depression in cancer patients [16]. In Pezzella 
and et al study, it was observed that in the 8-week 
amitriptyline recipient group, MARDS was reduced by more 
than 50% in 37.9% of patients, and this reduction was 43.7% 
in paroxetine recipients, which patients were more tolerant 
of amitriptyline [17]. 
In Thompson and et al study, it was observed that 
administration of mirtazapine could improve sleep 
disturbance, nausea and appetite in 19% of patients, but did 
not significantly reduce depression in patients [18]. 
In some studies, antidepressant drugs did not have a 
significant effect on patients' depression, for example in 
Musselman and et al study; it was observed that 
administration of 6-week Paroxetine and Dosipramine could 
not significantly reduce the depression rate toward placebo 
group [19]. 
In Marrow and et al study, it was observed that 8-week 
administration of Paroxetine couldn’t reduce vitality and 
depression rate towards placebo group [20].  
It seems that prescribing antipsychotics at a shorter 
duration of therapy reduces their effect on depression in 
patients. In the present study, it was observed that the 
administration of antidepressant drugs such as fluoxetine 
could have a significant positive effect on improving the 
quality of life of patients. 
 
CONCLUSION  
Results showed that Administration of fluoxetine in 
patients could improve some aspects of quality of life and 
general health, but it did not have significant effect on some 
aspects of quality of life and general health, that probably 
due to the short duration of fluoxetine administration in 
patients in this study which need for more studies in future. 
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